Matt Krause
Keine laufenden Positionen mehr
Profil
Matt Krause worked as a Senior Director of Human Resources at CV Therapeutics, Inc. and Amyris, Inc. before becoming the Vice President of Human Resources at Global Blood Therapeutics, Inc. He received his undergraduate degree from The California State University and his graduate degree from the University of Oregon.
Ehemalige bekannte Positionen von Matt Krause
| Unternehmen | Position | Ende |
|---|---|---|
| AMYRIS, INC. | Personalreferent | - |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Personalreferent | - |
| GLOBAL BLOOD THERAPEUTICS, INC. | Personalreferent | - |
Ausbildung von Matt Krause
| The California State University | Undergraduate Degree |
| University of Oregon | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AMYRIS, INC. | Process Industries |
| Private Unternehmen | 2 |
|---|---|
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
